These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11593051)

  • 1. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.
    Maurel J; Zorrilla M; Puertolas T; Antón A; Herrero A; Artal A; Alonso V; Martinez-Trufero J; Puertas MM
    Anticancer Drugs; 2001 Oct; 12(9):713-7. PubMed ID: 11593051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
    Brand R; Capadano M; Tempero M
    Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
    Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
    Schmid P; Schweigert M; Beinert T; Flath B; Sezer O; Possinger K
    Invest New Drugs; 2005 Mar; 23(2):139-46. PubMed ID: 15744590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of gemcitabine using a once every 2 weeks schedule.
    Vermorken JB; Guastalla JP; Hatty SR; Seitz DE; Tanis B; McDaniels C; Clavel MD
    Br J Cancer; 1997; 76(11):1489-93. PubMed ID: 9400947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
    Syrios J; Kouroussis C; Kotsakis A; Kentepozidis N; Kontopodis E; Kalbakis K; Vardakis N; Hatzidaki D; Polyzos A; Georgoulias V;
    Minerva Ginecol; 2019 Jun; 71(3):182-190. PubMed ID: 30727721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.
    Venugopal B; Awada A; Evans TR; Dueland S; Hendlisz A; Rasch W; Hernes K; Hagen S; Aamdal S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):785-92. PubMed ID: 26289594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
    Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
    J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
    Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
    Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
    J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
    Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
    Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
    Mekhail T; Hutson TE; Elson P; Budd GT; Srkalovic G; Olencki T; Peereboom D; Pelley R; Bukowski RM
    Cancer; 2003 Jan; 97(1):170-8. PubMed ID: 12491518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
    Schmid P; Akrivakis K; Flath B; Grosse Y; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Aug; 10(7):625-31. PubMed ID: 10507311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
    Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
    Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
    Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.